Mesenchymal Stromal Cells Emerge as Powerful Liver Disease Healers

Liver disease kills millions annually, yet curative options beyond transplantation remain limited. Mesenchymal stromal cells (MSCs), first isolated from bone marrow by Friedenstein decades ago, have emerged as a compelling regenerative medicine candidate due to their low immunogenicity, multilineage differentiation capacity, and powerful paracrine activity. This 2025 systematic review by Huang, Cheng, and colleagues synthesizes the mechanistic, preclinical, and early clinical evidence supporting MSC-based liver therapy.

At the immunological level, MSCs function as dynamic 'medicinal signaling cells.' They redirect hepatic macrophages from pro-inflammatory M1 to anti-inflammatory M2 phenotypes via TSG-6 and IL-10 secretion. Simultaneously, they suppress CD4+ T-cell activation through IDO-mediated tryptophan depletion, block pathogenic T-cell trafficking by downregulating CXCL9/10/11 chemokines, and induce T-cell apoptosis via the Fas/FasL pathway. MSC-derived extracellular vesicles (EVs) further dampen B-cell activation through MAPK and NF-κB inhibition. Together, these actions restore immune homeostasis in chronically inflamed liver tissue.

Regarding fibrosis—the hallmark of progressive liver disease—MSCs directly target activated hepatic stellate cells (HSCs), the principal fibrosis-driving cell type. They suppress fibrotic markers (α-SMA, Col1α1, vimentin), inhibit HSC proliferation via paracrine factors including FSTL1 and HGF, and intercept pro-fibrotic signaling through Notch pathway suppression and STAT1/STAT3 rebalancing. MSC-secreted MMPs (MMP-1, MMP-9) actively degrade deposited collagen while TIMP downregulation prevents reaccumulation, effectively reversing established fibrosis.

For regeneration, MSCs release HGF and VEGF to drive hepatocyte proliferation and neovascularization, respectively. Their exosomes carry miRNAs and proteins that upregulate HGF expression in HSCs, creating an indirect regenerative loop. Preclinical models of chemical-induced, alcoholic, and non-alcoholic fatty liver injury consistently show restored liver function, reduced injury markers, and structural repair following MSC administration. Preliminary clinical trials—including allogeneic infusion studies in cirrhosis and acute-on-chronic liver failure—confirm safety profiles and suggest meaningful survival benefits in end-stage disease.

Despite this promise, significant translational barriers remain. Cell source heterogeneity produces inconsistent therapeutic potency across preparations. MSC homing to injured liver tissue is inefficient, limiting engraftment. Standardized manufacturing protocols and quality control benchmarks are largely absent. Emerging solutions include CRISPR-based gene editing to enhance MSC homing and immunomodulatory capacity, engineered exosome delivery platforms that bypass cell viability concerns, and biomaterial scaffolds that localize MSCs within the hepatic microenvironment. The review positions these converging technologies as the next frontier for translating MSC biology into routine clinical practice.